| scholarly article | Q13442814 |
| P2093 | author name string | Aron M Geurts | |
| Robert R Montgomery | |||
| Hartmut Weiler | |||
| Sandra L Haberichter | |||
| Veronica H Flood | |||
| Qizhen Shi | |||
| Jessica Garcia | |||
| Scot A Fahs | |||
| Mark Zogg | |||
| Jeremy G Mattson | |||
| P2860 | cites work | Biochemistry and genetics of von Willebrand factor | Q22003890 |
| Genome engineering using the CRISPR-Cas9 system | Q22122027 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis | Q28586884 | ||
| Insights from von Willebrand disease animal models | Q28592716 | ||
| Thrombotic thrombocytopenia induced in dogs and pigs. The role of plasma and platelet vWF in animal models of thrombotic thrombocytopenic purpura | Q33489821 | ||
| Platelets have more than one binding site for von Willebrand factor | Q33821754 | ||
| Crucial role for the VWF A1 domain in binding to type IV collagen | Q35252688 | ||
| Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice | Q35881502 | ||
| Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease | Q36193201 | ||
| von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). | Q37100261 | ||
| Collagen binding provides a sensitive screen for variant von Willebrand disease | Q37367262 | ||
| Intracellular trafficking of factor VIII to von Willebrand factor storage granules | Q37377963 | ||
| Gene deletions correlate with the development of alloantibodies in von Willebrand disease | Q40922128 | ||
| Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease | Q45856650 | ||
| A novel F8 -/- rat as a translational model of human hemophilia A. | Q45865994 | ||
| Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease | Q45874158 | ||
| Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. | Q45936667 | ||
| Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease | Q68933421 | ||
| Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor | Q70237272 | ||
| Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups | Q71579909 | ||
| Rat Genome Databases, Repositories, and Tools | Q92951348 | ||
| P4510 | describes a project that uses | CRISPR-Cas method | Q17310682 |
| P433 | issue | 1 | |
| P921 | main subject | CRISPR | Q412563 |
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 64-71 | |
| P577 | publication date | 2019-12-29 | |
| P1433 | published in | Research and Practice in Thrombosis and Haemostasis | Q50817799 |
| P1476 | title | A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9 | |
| P478 | volume | 4 |
Search more.